Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MaaT Pharma SA

Latest From MaaT Pharma SA

MaaT Has Pathway To Microbiome Market Mapped Out

Freed from a lengthy FDA clinical hold, the French biotech is advancing on a variety of fronts, business development head Savita Bernal tells Scrip.

Business Strategies Clinical Trials

MaaT’s FDA Woes Highlight Rocky Regulatory Path For Microbiome-Based Therapies

The French firm's lead microbiome therapy has been on clinical hold in the US for a year and continuing concerns about MaaT's 'pooling' approach (mixing donations from multiple donors) suggests the wait to restart trials will not be a short one.

Clinical Trials Infectious Diseases

After A Bumper 2021, How French Biotech Is Surviving Market Doldrums

French Biotech In Focus: Amid a global biotech funding boom last year, French biotech saw a rise in the number of high-value financing rounds while its firms adopt savvy licensing strategies.

France Financing

From Big Pharma To Biotech: Rare Disease R&D Blossoms As French Biotech Pipelines Mature

French Biotech In Focus: While R&D at French biopharma firms in general reflects worldwide trends for oncology and neurology, rare diseases are coming more to the fore, backed by the country’s world-class academic institutions and US FDA recognition.

France Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals